Search
Calcitriol
go.drugbank.com/drugs/DB00136ApprovedInvestigationalNutraceuticalIn addition to promoting fatty acid synthesis and inhibiting lipolysis, calcitriol has been demonstrated to increase energy efficiency by suppressing UCP2 expression, which is modulated by signaling pathways … Renal production of calcitriol is stimulated in response to PTH, low calcium and low phosphate [A26353].
Synonyms: (1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol, (1α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triolChloroxine
go.drugbank.com/drugs/DB01243ApprovedWithdrawnChloroxine is a compound used in some shampoos for the treatment of dandruff and seborrheic dermatitis of the scalp.
Chloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigationalBoth can be given as intrathecal injections for peripheral and central nerve block, but only the preservative-free formulation can be used for lumbar and caudal epidural blocks. … [A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387]
Beclamide
go.drugbank.com/drugs/DB09011ExperimentalIt was studied in the 1950s for generalised tonic-clonic seizures but was not effective for absence seizures. … Beclamide (N-benzyl-B-chloropropionamide) is a no longer used drug that possesses anticonvulsant and sedative activity.
Suvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Nilutamide
go.drugbank.com/drugs/DB00665ApprovedInvestigationalNilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). … To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Categories: Antiandrogens, non-steroidalTyrosine-protein phosphatase non-receptor type substrate 1
go.drugbank.com/bio_entities/BE0010650TargetHumansIn response to THBS1, involved in ROS signaling in non-phagocytic cells, stimulating NADPH oxidase-derived ROS production (PubMed:24511121)
Polypeptides: Tyrosine-protein phosphatase non-receptor type substrate 1Serelaxin
go.drugbank.com/drugs/DB05794Investigationalbones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy. … Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic
Mirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigationalOn February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). … [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation
Synonyms: N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE N-((2R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOANILINO)BENZAMIDE, (-)-N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDETrastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigational[A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]